NASDAQ:KALA

Kala Pharmaceuticals - KALA Stock Forecast, Price & News

$0.34

+0.01 (+3.07%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.31
▼
$0.34
50-Day Range: $0.30
▼
$0.42
52-Week Range: $0.28
▼
$3.61

Volume: 1.03 million shs
Average Volume: 1.03 million shs
Market Capitalization: $24.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.13

Kala Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 829.8% Upside
$3.13 Price Target
Short Interest: Healthy
3.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.35
Upright™ Environmental Score
News Sentiment: 0.68
Based on 13 Articles This Week
Insider Trading: Selling Shares
$1.42 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.27) to ($0.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

109th out of 1,135 stocks

Pharmaceutical Preparations Industry

39th out of 557 stocks

3.2

Analyst's Opinion

Consensus Rating
Kala Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.13, Kala Pharmaceuticals has a forecasted upside of 829.8% from its current price of $0.34.
Amount of Analyst Coverage
Kala Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.05% of the float of Kala Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Kala Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kala Pharmaceuticals has recently decreased by 11.22%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kala Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kala Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kala Pharmaceuticals has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kala Pharmaceuticals is -1.35.

2.6

News and Social Media Coverage

News Sentiment
Kala Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Kala Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
18 people have searched for KALA on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Kala Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kala Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,418,911.00 in company stock.
Percentage Held by Insiders
20.04% of the stock of Kala Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
52.81% of the stock of Kala Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kala Pharmaceuticals are expected to grow in the coming year, from ($1.27) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kala Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kala Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kala Pharmaceuticals has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kala Pharmaceuticals (NASDAQ:KALA) Stock

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Kala Pharmaceuticals Stock Performance

KALA Stock traded up $0.01 during mid-day trading on Friday, hitting $0.34. The company had a trading volume of 1,031,977 shares, compared to its average volume of 1,027,533. The company has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.71. Kala Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $3.61. The company has a quick ratio of 2.68, a current ratio of 3.00 and a debt-to-equity ratio of 5.04.

Kala Pharmaceuticals (NASDAQ:KALA - Get Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.09). Kala Pharmaceuticals had a negative return on equity of 562.06% and a negative net margin of 1,628.91%. The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $3.11 million. During the same period last year, the firm posted ($0.49) earnings per share. On average, research analysts predict that Kala Pharmaceuticals will post -1.27 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright cut their price target on Kala Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th. Wedbush cut their target price on Kala Pharmaceuticals from $6.00 to $3.00 and set a "na" rating for the company in a research report on Tuesday, May 17th.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. sold 1,250,000 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $0.65, for a total value of $812,500.00. Following the sale, the insider now owns 9,624,613 shares in the company, valued at $6,255,998.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 2,695,097 shares of company stock worth $1,418,911. 20.04% of the stock is currently owned by insiders.

Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Stock News Headlines

August 13, 2022 | seekingalpha.com

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | seekingalpha.com

Kala Pharma sees large fall in operating expenses for H2, FY, extends expected cash runway

August 11, 2022 | finance.yahoo.com

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 11, 2022 | finance.yahoo.com

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates

August 11, 2022 | finance.yahoo.com

Kala Pharma Stops Working On Certain Preclinical Programs, Extends Cash Runway Into 2024

August 10, 2022 | morningstar.com

Kala Pharmaceuticals Inc Stock News

August 8, 2022 | finance.yahoo.com

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

August 4, 2022 | finance.yahoo.com

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

July 6, 2022 | finance.yahoo.com

Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade

June 2, 2022 | finance.yahoo.com

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 27, 2022 | nasdaq.com

Bitcoin Now Buys You the Greatest Amount of Kala Pharmaceuticals in the Past Year

May 24, 2022 | seekingalpha.com

H.C. Wainwright analyst lowers Kala Pharmaceuticals' price target

May 23, 2022 | uk.investing.com

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022 | finance.yahoo.com

This Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop Portfolio

May 23, 2022 | nasdaq.com

Alcon To Acquire EYSUVIS, INVELTYS From Kala Pharma

May 23, 2022 | seekingalpha.com

Kala Pharmaceuticals plans to sell EYSUVIS and INVELTYS to Alcon

May 17, 2022 | seekingalpha.com

Kala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 17, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Kala Pharmaceuticals

May 16, 2022 | seekingalpha.com

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | benzinga.com

Recap: Kala Pharmaceuticals Q1 Earnings

May 15, 2022 | markets.businessinsider.com

What Wall Street expects from Kala Pharmaceuticals's earnings

May 13, 2022 | seekingalpha.com

Kala Pharmaceuticals Q1 2022 Earnings Preview

May 9, 2022 | finance.yahoo.com

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 3, 2022 | seekingalpha.com

Kala expands commercial, Medicare coverage for dry eye disease therapy Eysuvis

May 3, 2022 | finance.yahoo.com

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Company Calendar

Last Earnings: 5/16/2022
Today: 8/13/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KALA
CUSIP: N/A
CIK: 1479419
Web: www.kalarx.com
Phone: (781) 996-5252
Fax: 781-642-0399
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.13
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +829.8%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-142,600,000.00
Net Margins: -1,628.91%
Pretax Margin: -1,552.90%
Return on Equity: -562.06%
Return on Assets: -92.23%

Debt

Debt-to-Equity Ratio: 5.04
Current Ratio: 3.00
Quick Ratio: 2.68

Sales & Book Value

Annual Sales: $11.24 million
Price / Sales: 2.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.26 per share
Price / Book: 1.29

Miscellaneous

Outstanding Shares: 72,590,000
Free Float: 58,046,000
Market Cap: $24.40 million
Optionable: Optionable
Beta: 1.04

Key Executives

Mr. Mark T. Iwicki (Age 56)
Chairman & CEO
Comp: $919.89k
Mr. Todd Bazemore (Age 52)
Pres & COO
Comp: $671.58k
Dr. Kim Brazzell Ph.D. (Age 69)
Head of R&D and Chief Medical Officer
Comp: $645.19k
Dr. Justin Hanes Ph.D.
Founder & Chair of the Scientific Advisory Board
Ms. Mary Reumuth CPA (Age 47)
CPA, CFO & Treasurer
Ms. Jill S. Steier
Exec. Director of Investor Relations & Corp. Communications
Mr. Eric L. Trachtenberg (Age 49)
Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Ms. Michele LaRussa (Age 52)
Sr. VP of Regulatory Affairs & Quality Assurance
Mr. Vincent Kosewski (Age 59)
Sr. VP of Manufacturing & Supply Chain Management
Mr. James Patnoe
Sr. VP of Market Access, Commercial Operations & Pricing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KALA Stock - Frequently Asked Questions

Should I buy or sell Kala Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View KALA analyst ratings or view top-rated stocks.
What is Kala Pharmaceuticals' stock price forecast for 2022?: 3 brokerages have issued 1 year price targets for Kala Pharmaceuticals' stock. Their KALA share price forecasts range from $1.50 to $4.00. On average, they predict the company's stock price to reach $3.13 in the next twelve months. This suggests a possible upside of 829.8% from the stock's current price.
View analysts price targets for KALA or view top-rated stocks among Wall Street analysts.
How have KALA shares performed in 2022?: Kala Pharmaceuticals' stock was trading at $1.21 at the beginning of 2022. Since then, KALA shares have decreased by 72.2% and is now trading at $0.3361.
View the best growth stocks for 2022 here.
When is Kala Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our KALA earnings forecast.
How were Kala Pharmaceuticals' earnings last quarter?: Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.09. The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $3.11 million. Kala Pharmaceuticals had a negative net margin of 1,628.91% and a negative trailing twelve-month return on equity of 562.06%. During the same quarter in the previous year, the firm earned ($0.49) EPS.
What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?: 1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kala Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).
When did Kala Pharmaceuticals IPO?: (KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
What is Kala Pharmaceuticals' stock symbol?: Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
Who are Kala Pharmaceuticals' major shareholders?: Kala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.49%), Vahanian & Associates Financial Planning Inc. (0.25%), Integrated Wealth Concepts LLC (0.21%), Northern Trust Corp (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Rajeev M Shah, Romulus K Brazzell and Todd Bazemore.
View institutional ownership trends.
How do I buy shares of Kala Pharmaceuticals?: Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kala Pharmaceuticals' stock price today?: One share of KALA stock can currently be purchased for approximately $0.34.
How much money does Kala Pharmaceuticals make?: Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $24.40 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.
How many employees does Kala Pharmaceuticals have?: The company employs 192 workers across the globe.
How can I contact Kala Pharmaceuticals?: Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.

This page (NASDAQ:KALA) was last updated on 8/14/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Kala Pharmaceuticals - KALA Stock Forecast, Price & News

Kala Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kala Pharmaceuticals (NASDAQ:KALA) Stock

Kala Pharmaceuticals Stock Performance

Analyst Ratings Changes

Insider Activity

KALA Stock News Headlines

KALA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KALA Stock - Frequently Asked Questions

Should I buy or sell Kala Pharmaceuticals stock right now?

What is Kala Pharmaceuticals' stock price forecast for 2022?

How have KALA shares performed in 2022?

When is Kala Pharmaceuticals' next earnings date?

How were Kala Pharmaceuticals' earnings last quarter?

What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?

What other stocks do shareholders of Kala Pharmaceuticals own?

When did Kala Pharmaceuticals IPO?

What is Kala Pharmaceuticals' stock symbol?

Who are Kala Pharmaceuticals' major shareholders?

How do I buy shares of Kala Pharmaceuticals?

What is Kala Pharmaceuticals' stock price today?

How much money does Kala Pharmaceuticals make?

How many employees does Kala Pharmaceuticals have?

How can I contact Kala Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™